


Scleroderma
systemic sclerosis

pss

SSc



M.H. Jokar


Dept. Rheumatology
Emam Reza Hospital

Overview

- Basics
- Epidemiology
- Pathogenesis
- Pathology
- Clinical features
- Laboratory evaluation

Basics

- *Definition:* A **systemic** disorder characterized by **accumulation of connective tissue** in the skin and visceral organs, causing structural and functional abnormalities
- *Etiology:* **Unknown**
- *Clinical characteristics:*
 - vascular damage
 - immune activation
 - excessive synthesis and deposition of extracellular matrix (fibrosis)




Pathogenesis

Uncontrolled and irreversible proliferation of normal connective tissue along with striking vascular changes

- Collagen
- Proteoglycans
- Fibronectin
- Laminin

EPIDEMIOLOGY OF SYSTEMIC SCLEROSIS

Peak age (years)	30–50
Sex distribution (F:M)	4:1
Prevalence rate (/100,000)	10–20
Annual incidence (/100,000)	1–2
Geography	Unrestricted
Genetic associations	?? DR5, DRw52, DR4
Relative risk	Unknown



Scleroderma

Etiology

Initiating factors are not known

& Numerous environmental agents (PVC)

& Drugs (Bleomycin, Pentecocine)

& Viruses


& Defective immunoregulation


↗ Autoantibodies

↗ Cellular autoimmunity

↗ Genetics and viruses

Pathogenesis





Genetic Risk

- The relative risk among first-degree: 13
- HLA DRB1*1104, DQA1*0501, DQB1*0301

Systemic Sclerosis (SSc) Susceptibility Genes

Locus	Chromosome	Associated SSc Subset
<i>HLA</i>	6	Various
<i>PTPN22</i>	1p3.2	Topo1+ positive
<i>NLRP1</i>	17p13.2	dcSSc, pulmonary fibrosis
<i>IRF5</i>	7q32	dcSSc
<i>STAT4</i>	2q32.3	lcSSc, ACA
<i>BANK1</i>	4q24	dcSSc
<i>TNFSF4</i>	1q25	SSc
<i>T-bet</i>	17.q21.32	SSc

Environmental Agents and Drugs

Implicated in Scleroderma-like Syndromes

Chemicals

Silica

Heavy metals

Mercury

Organic chemicals

 Vinyl chloride

 Benzene

 Toluene

 Trichloroethylene

Drugs

Bleomycin

Pentazocine

Taxol

Cocaine

Dietary Supplement/Appetite Suppressants

L-tryptophan (contamination)

Mazindol


Fenfluramine

Diethylpropion


INFECTIOUS AGENTS: VIRUSES

- Human cytomegalo- virus (hCMV)
- Parvovirus B19

Vasculopathy



Fibrosis



*Cause of excess production
of connective tissue matrix:*

PDGF

TGF beta

IL1


MICROCHIMERISM


PATHOLOGY

- In early-stage:
inflammatory cell infiltrates
- Noninflammatory
proliferative/obliterative vasculopathy
Fibrosis

Vascular Pathology



- Intimal proliferation
- Medial hypertrophy





Tissue Fibrosis


- Excessive accumulation of:
- Fibrillar collagens
- Fibronectin
- Elastin
- Proteoglycans,
- Cartilage oligomeric matrix protein (COMP)





Classification

- **Diffuse**
- **Limited**
- **Localized(morphea,linear)**



Clinical Features:

Fibrous thickening affects:

- **Skin**
- **Muscles**
- **Joints**
- **Tendons**
- **Certain internal organs especially esophagus, intestinal tract, lungs and kidneys**

Raynaud's phenomenon

- **An episodic self-limited and reversible vasomotor disturbance manifested as color changes bilaterally in the fingers, toes, and sometimes ears nose and lips**
- **Color changes: pallor, cyanosis, erythema**
- **Numbness, tingling, pain on recovery**





Scleroderma and Raynaud's

- **Frequency :**


Diffuse 85%


Limited 95%

- **In 70% first presentation**

Skin

- Edematous
- Hardening
- Softening







DOIA

[c] University Erlangen,
Department of Dermatology
Phone: (+49) 9131-85-2727






DOIA

(c) University Erlangen,
Department of Dermatology
Phone: (+49) 9131-85-2327













(c) University Erlangen,
Department of Dermatology
Phone: (+49) 91 31- 85 - 2727














Gastrointestinal Tract

Esophagus

- Esophageal dysmotility
- Dysphagia
- GER

Small bowel

- Diarrhea
- Malabsorption
- Deficient peristalsis

Large bowel


- Diarrhea
- Constipation
- Obstruction
- Perforation




Pulmonary Features

- At least two-thirds of SSc patients and is now the leading cause of death
- Pulmonary fibrosis
- Vascular lesions :Pulmonary hypertension

INEXT



Next




Renal Features

- Renal failure was the leading cause of death in SSc until the advent of effective treatment
- Mostly in diffuse cutaneous scleroderma
- Renal crisis characterized by malignant hypertension, which can progress rapidly to renal failure

Sicca Syndrome





Scleroderma

Joints

- Polyarthralgia
- Polyarthritits
- Stiff painful muscles

Heart

- Arrhythmias
- Conduction defects
- Pericarditis
- Congestive Cardiac failure



Immunological tests

- **Scleroderma 70 antibody (*SC1-70*)**

Associated with diffuse disease

- **Anticentromere antibodies (*ACA*)**

Associated with limited disease

Classification criteria

Major criteria

- skin change in any location proximal to the metacarpophalangeal joints

Minor criteria:

1. sclerodactyly,
2. digital pitting scars of fingertips or loss of digital finger pad substance,
3. bibasilar pulmonary fibrosi

Differential Diagnosis

- Digital sclerosis of diabetes mellitus
- Amyloidosis
- Scleroderma
- Scleromyxedema
- Human graft-versus-host disease

Differential Diagnosis


- Eosinophilic fasciitis
- Porphyria cutanea tarda
- Pentazocine-induced scleroderma

Disorders characterized by similar internal organ involvement

- Primary pulmonary hypertension
- Primary biliary cirrhosis
- Idiopathic pulmonary fibrosis

THE NATURAL HISTORY OF SYSTEMIC SCLEROSIS BY CLASSIFICATION OF DISEASE

— diffuse — limited ■ accrual of visceral involvement



Linear scleroderma



Morphea

